• DARZALEX® Study Data Show High Response Rate americanpharmaceuticalreview
    September 17, 2019
    The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the randomized Phase 2 GRIFFIN (MMY2004) study showing that the addition of DARZALEX® (daratumumab) to bortezomib ...
PharmaSources Customer Service